Patient willingness to pay for preventive measures in primary care: a study of five GPs in a German community

Wiesemann, Armin; Mueller-Buehl, Uwe; Scheidt, Reginald; Boehme, W; Scheuermann, W.

doi:10.1007/s00038-004-3039-5

Cited by 5 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jensen 26 showed the importance for sustainability of beneficiaries' willingness and ability to pay for health services. Wiesemann and others 27 showed that participants of educational courses are willing to pay for preventive health measures and this was without correlation with income. Finally, Bossert 28 and Shediac-Rizkallah and Bone 29 have identified capacity building as crucial for the sustainability of health programs.…”

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness of a Community-Based Approach Intertwined with a Vertical Aedes Control Program

Baly¹,

Toledo²,

Vanlerberghe³

et al. 2009

Am J Trop Med Hyg

View full text Add to dashboard Cite

We compared in a 5-year intervention study the cost-effectiveness of community-based environmental management intertwined with routine vertical Aedes control and of routine vertical control only. At baseline (year 2000), Aedes infestation levels and economic costs for vector control were comparable in intervention and control areas (house index, 2.23% versus 2.21% and US$21 versus US$24/yr/inhabitant, respectively). By 2004, house indices became 0.22% versus 2.36% and the costs were 29.8 US$ versus 36.7 US$/yr/inhabitant, respectively. The community cost made up 38.6% of the total economic cost in 2004 in the intervention areas against 23.5% in 2000. The average cost-effectiveness ratio for the intervention period 2001-2004, expressed as the societal cost incurred for the reduction (from baseline) of Aedes foci, was US$831.1 per focus in the intervention areas versus US$2,465.6 in the control areas. The intervention produced economic savings and health benefits that were sustained over the whole observation period.

show abstract

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness of a Community-Based Approach Intertwined with a Vertical Aedes Control Program

Baly¹,

Toledo²,

Vanlerberghe³

et al. 2009

Am J Trop Med Hyg

View full text Add to dashboard Cite

show abstract

“…Whilst a number of studies have used willingness-topay (WTP) to estimate the benefits of health promotion or preventative programmes (e.g. [36][37][38][39][40]), the role and influence of non-health benefits on willingnessto-pay for health promotion programmes has not yet been explored. Furthermore, there have only been limited attempts by health economists to capture non-use values through the CV method [33,[41][42][43], despite an extensive literature on altruism in economics and it's role within willingness-to-pay and cost-benefit analysis (e.g.…”

Section: Introductionmentioning

confidence: 99%

Measuring the benefits of health promotion programmes: Application of the contingent valuation method

Borghi¹,

Jan²

2008

Health Policy

View full text Add to dashboard Cite

“…Even though the CV method is often used, experience of WTP analysis in Germany is limited to a few studies. [11][12][13] Moreover, very little knowledge exists of specific factors influencing WTP.…”

Section: Willingness To Pay (Wtp)mentioning

confidence: 99%

Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women

Rasch¹,

Hodek²,

Runge³

et al. 2009

PharmacoEconomics

View full text Add to dashboard Cite

Menopause is a natural physiological event that usually begins in women between the ages of 48 and 55 years. In many cases, this event is associated with unpleasant somatic-vegetative, urogenital or psychological symptoms. To test the health and social demographic factors (especially household income level) that influence willingness to pay (WTP) for a new hormone-free treatment in women of menopausal age. 1365 women between the ages of 45 and 73 years were surveyed about their health and WTP for the new treatment. WTP was evaluated with a closed-ended binary questionnaire (four groups with different levels of co-payment between euro15 and euro60), using the contingent valuation method. The average WTP was calculated according to the area under the demand function. Factors contributing to payment readiness were examined by means of binary logistic regression. WTP was significantly affected by women's opinion of the new medication, the level of co-payment required, net household income, whether currently in treatment for menopausal symptoms, and Menopause Rating Scale (MRS) values. Compared with other factors, the level of co-payment was predicted to have a negative impact on WTP. Income level is an important factor in WTP and correlates highly with several other health-related variables (WHO-5 index, MRS value, receipt of other menopause medicines and existing co-morbidity). The average co-payment that our group of women was willing to pay was between euro17 and euro35 per month, or euro24 to euro42 for women who were currently receiving treatment for symptoms of menopause. While interpreting the results, it should be considered that the hypothetical therapy was assumed to be a new non-reimbursable alternative to conventional therapy offered under the existing statutory framework for health insurance in Germany. Despite some methodological limitations, these results are useful for examining the factors affecting WTP and incremental utilities for future medicine dealing with menopause.

show abstract

Patient willingness to pay for preventive measures in primary care: a study of five GPs in a German community

Cited by 5 publications

References 32 publications

Cost-Effectiveness of a Community-Based Approach Intertwined with a Vertical Aedes Control Program

Cost-Effectiveness of a Community-Based Approach Intertwined with a Vertical Aedes Control Program

Measuring the benefits of health promotion programmes: Application of the contingent valuation method

Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women

Contact Info

Product

Resources

About